良性声带病变及原发性肌紧张性发声障碍患者接受嗓音治疗后的长期患者报告结局
Long-Term Patient-Reported Outcomes Following Voice Therapy in Individuals With Benign Vocal Fold Lesions and Primary Muscle Tension Dysphonia.
文献信息
| PMID | 42919719 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Merve Önal |
| 作者单位 | Doctoral Program in Speech and Language Disorders Therapy, Graduate School of Health Sciences, Üsküdar University, Istanbul, Turkiye; Department of Otorhinolaryngology, Unit of Audiology and Speech-Language Pathology, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, 34093, Turkiye. Electronic address: dktmerveonal@gmail.com. |
| 期刊 | Journal of voice : official journal of the Voice Foundation |
| SCI 分区 | Q1 |
| IF | 2.4 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 咽喉科 |
中文摘要
目的： 本研究探讨了患有良性声带病变（BVFLs）和原发性肌紧张性发声障碍（PMTD）的成人接受嗓音治疗后的长期患者报告结局。
方法： 这项回顾性横断面研究纳入了64名在2021年至2023年间完成嗓音治疗的成人。参与者在平均46.98个月（标准差=7.95；范围33-64个月）的随访后接受评估，使用嗓音障碍指数-10（VHI-10）、土耳其语扩展版患者嗓音治疗感知（PPVT）问卷以及人口学问卷。采用非参数分析检验患者报告结局与治疗以来时间之间的关联。
结果： 参与者报告了积极的长期结局。VHI-10平均得分为12.06（标准差=8.81）。较低的嗓音相关障碍与更大的感知治疗获益（ρ=-0.408，P<0.01）和更大的感知改善（ρ=-0.512，P<0.01）相关。治疗以来时间与任何患者报告结局指标均无显著关联。大多数参与者（60.9%）报告显著或重大改善，认为嗓音治疗有益，能够满足日常交流需求，且不需要额外评估或治疗。尽管症状复发常见，但症状通常为间歇性而非持续性。患者报告结局在声带小结、PMTD及其他BVFL/混合诊断组之间无显著差异。
结论： BVFLs和PMTD患者感知的嗓音治疗获益似乎在治疗后持续数年。长期结局不仅体现在症状负担上，还体现在保留的功能性嗓音使用和患者对康复的感知上。综上所述，这些发现支持采用多维、以患者为中心的方法来评估嗓音治疗结局的持久性。
英文摘要
OBJECTIVES: This study investigated long-term patient-reported outcomes following voice therapy in adults with benign vocal fold lesions (BVFLs) and primary muscle tension dysphonia (PMTD).
METHODS: This retrospective cross-sectional study included 64 adults who completed voice therapy between 2021 and 2023. Participants were assessed after a mean follow-up of 46.98 months (SD = 7.95; range, 33-64 months) using the Voice Handicap Index-10 (VHI-10), the expanded Turkish adaptation of the Patient Perception of Voice Therapy (PPVT) questionnaire, and a demographic questionnaire. Nonparametric analyses were used to examine associations between patient-reported outcomes and time since treatment.
RESULTS: Participants reported positive long-term outcomes. The mean VHI-10 score was 12.06 (SD = 8.81). Lower voice-related handicap was associated with greater perceived treatment benefit (ρ = -0.408, P < 0.01) and greater perceived improvement (ρ = -0.512, P < 0.01). Time since treatment was not significantly associated with any patient-reported outcome measure. Most participants (60.9%) reported significant or major improvement, considered voice therapy beneficial, were able to meet their daily communication demands, and did not require additional evaluation or treatment. Although symptom recurrence was common, symptoms were typically intermittent rather than persistent. Patient-reported outcomes did not differ significantly across the vocal nodule, PMTD, and other BVFL/mixed diagnoses groups.
CONCLUSION: The benefits of voice therapy perceived by patients with BVFLs and PMTD appear to persist for several years after treatment. Long-term outcome is reflected not only in symptom burden, but also in preserved functional voice use and patients' perceptions of recovery. Taken together, these findings support a multidimensional, patient-centered approach to evaluating the durability of voice therapy outcomes.